Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont, Saskia Verkaik, Fanny Krantz, Paul G. Pearson, Roger Ulrich, and Allard Kaptein

Acerta Pharma BV, Oss, The Netherlands

Received June 13, 2017; accepted August 31, 2017

ABSTRACT

Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns. Herein we describe the pharmacologic characterization of BTK inhibitor acalabrutinib [compound 1, ACP-196 (4-[8-amino-3-[(2S)-1-butyl]-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide]. Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK. Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential. Acalabrutinib demonstrated higher biochemical and cellular selectivity than ibrutinib and spebrutinib (compounds 2 and 3, respectively). Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited. Determination of the inhibitory potential of anti-immunoglobulin M–induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor. In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib. Preclinical and clinical studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy. Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination. In these healthy individuals, a single oral dose of 100 mg showed approximately 99% median target coverage at 3 and 12 hours and around 90% at 24 hours in peripheral B cells. In conclusion, acalabrutinib is a BTK inhibitor with key pharmacologic differentiators versus ibrutinib and spebrutinib and is currently being evaluated in clinical trials.

Introduction

Bruton tyrosine kinase (BTK) is a TEC–family nonreceptor protein kinase expressed in B cells, myeloid cells, mast cells, and platelets. B cell receptor (BCR)–mediated signaling is essential for activation, proliferation, and survival of B lymphocytes, and BTK is an essential component of the BCR signaling cascade (Hendriks et al., 2014). Expression of BTK in B cell leukemias and lymphomas has also been reported (de Weers et al., 1993; Katz et al., 1994). Furthermore, BTK is involved in the regulation of FcyR signaling in myeloid cells (Jongstra-Bilen et al., 2008) and in mast cell degranulation after FceR1 activation (Ellmeier et al., 2011). These features of BTK render it a very attractive target in treating B cell malignancies (Hendriks et al., 2014) and autoimmune disease (Whang and Chang, 2014). Several small-molecule inhibitors of BTK have progressed to the clinic (Table 1) and collectively demonstrate clinical validation of BTK inhibition in B cell malignancies. Most of the BTK inhibitors listed in Table 1 have been reported to bind in a covalent fashion to a cysteine residue (Cys481) at the rim of the ATP binding pocket of BTK (Pan et al., 2007; Norman, 2016). To date, ibrutinib is the only BTK inhibitor that has received marketing authorization for the treatment of B cell malignancies (Ponader and Burger, 2014); however, it is associated with adverse events not likely due to inhibition of BTK function, based on clinical observations in patients with X-linked agammaglobulinemia who have dysfunctional BTK (Winkelstein et al., 2006). These
Ibrutinib-mediated adverse events include rash, diarrhea, arthralgias or myalgias, atrial fibrillation, and major hemorrhage (Byrd et al., 2013; Wang et al., 2013; O’Brien et al., 2014), some of which may be explained by inhibition of off-target kinases EGFR, TEC, ITK, and TXK (Honigberg et al., 2010). Spebrutinib is another covalent BTK inhibitor that was subject to clinical evaluation; although it was reportedly a highly selective inhibitor (Evans et al., 2013), doses needed to achieve a partial response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma are higher than for ibrutinib (Brown et al., 2016).

Here we report the differentiated profile of BTK inhibitor acalabrutinib [compound 1, ACP-196 (1,4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide)]. Acalabrutinib is a small-molecule irreversible BTK inhibitor (Fig. 1) that shows encouraging clinical activity and safety in patients with relapsed or refractory CLL (Byrd et al., 2016). The preclinical profile of acalabrutinib and a few additional compounds was compared with ibrutinib.

### Table 1

| Compound          | Company          | Stage of Development | Primary Therapeutic Area | Reference            |
|-------------------|------------------|----------------------|--------------------------|----------------------|
| Ibrutinib (Imbruvica) | J&J, AbbVie     | Approved             | Oncology                 | Byrd et al. (2015)   |
| Acalabrutinib (ACP-196) | Acerta Pharma  | Phase 3              | Oncology                 | Byrd et al. (2016)   |
| BGB-3111          | BeTheGene        | Phase 3              | Oncology                 | Tam et al. (2015)    |
| Spebrutinib (CC-292) | Celgene         | Phase 2              | Autoimmune               | Evans et al. (2013)  |
| Evobrutinib (M2951) | Merck Serono    | Phase 2              | Autoimmune               | Grenninglo (2016)    |
| PRN-1068          | Principia        | Phase 2              | Autoimmune               | Smith et al. (2015)  |
| LY337641 (HM-71224) | Lilly           | Phase 2              | Autoimmune               | Park et al. (2016)   |
| M7583             | Merck Serono    | Phase 1/2            | Oncology                 | Bender et al. (2016) |
| Tirabrutinib (GS-4059) | Gilead          | Phase 1              | Oncology                 | Walter et al. (2016) |
| AC-0058STA        | ACEA Biosciences | Phase 1              | Autoimmune               | —                    |

*Development stage of most advanced clinical program, based on ClinicalTrials.gov. Additional potential covalent BTK inhibitors include CT-1530, BMS-986195, and DTRMWXHS-12.

---

**Fig. 1.** (Left) Chemical structures of clinical irreversible binding BTK inhibitors. (Top right) Front view of a binding model of acalabrutinib (gold) in the ATP binding pocket of BTK. (Bottom right) Second view of the model, showing the hydrogen bonding interaction of the 2-pyridylamide moiety with Ser538 and Asp539.
Materials and Methods

Biochemical Kinase Assays. BTK and ITK enzyme activity was measured using the immobilized metal ion affinity-based fluorescence polarization (IMAP) assay. BTK enzyme (Millipore, Dundee, UK) or ITK enzyme (Millipore) was diluted to 16 and 54 nM, respectively, in kinase reaction (KR) buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween 20, 0.1% NaN3, 1 mM dithiothreitol, and 2 mM MnCl2, pH 7.5). Serial dilutions were made from 1 mM to 31.6 nM of test compounds were made in 100% dimethylsulfoxide (DMSO). The dilutions in DMSO were then diluted 25-fold in KR buffer. Final compound concentrations ranged from 10 μM to 0.316 nM. Test compound (5 μl/well) in KR buffer (final DMSO concentration of 1%) was mixed with 5 μl/well BTK or ITK enzyme (final concentration of 4 and 8 nM for BTK and ITK, respectively). Test compounds and kinase enzyme were preincubated 1 hour at room temperature before the addition of 5 μl/well of 200 nM fluorescein-labeled substrate peptide (Blk/Lyntide substrate; Molecular Devices, Sunnyvale, CA) in KR buffer. The final peptide substrate concentration was 50 nM. The kinase assay was started by adding 5 μl/well of 20 μM ATP in KR buffer (final ATP concentration of 5 μM ATP, Km ATP). After incubation for 2 hours at room temperature, the enzyme reaction was stopped by adding 40 μl/well IMAP Progressive Binding Solution (Molecular Devices), according to the manufacturer’s instructions, using 60% 1x buffer A and 40% 1x buffer B with 800x-diluted beads. After 60-minute incubation at room temperature in the dark, the fluorescence polarization signal was read. Fluorescence at 535 nm was measured using parallel and perpendicular filters to determine differences in rotation due to binding of the phosphorylated substrate peptide to the beads. Values were calculated as the percentage of the difference in readout (delta millipolarization) of the controls with and without ATP. IC50 values were determined by curve fitting of the experimental results using Dotmatics software (Dotmatics, Stortford, UK).

Inhibitory activity on TEC was measured using the LanthaScreen assay (Thermo Fisher Scientific, Carlsbad, CA) according to the manufacturer’s protocol, with a final concentration of 1 nM TEC enzyme (Life Technologies, Carlsbad, CA) and 2 nM Eu-anti-His antibody (Invitrogen, Carlsbad, CA). Serial dilutions of test compounds were prepared as described above for the BTK and ITK IMAP assays. Test compounds, TEC enzyme/antibody mix, and Tracer 178 (final concentration of 1 nM; Invitrogen) were mixed and incubated for 2 hours at room temperature in the dark, prior to reading the time-resolved fluorescence energy transfer signal at 615 and 665 nm. A ratio of 665/615 was used to calculate values expressed as the percentage of the difference in readout (S/N) of the controls with and without the tracer. IC50 values were determined by curve fitting of the experimental results using Dotmatics. Kinase activity was measured using the Z’LYTE assay (Thermo Fisher Scientific) for the following: BMX, TXK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. A 10-point dose response was generated with 1 hour incubation of the test compound with the kinase prior to initiation of the kinase reaction by the addition of ATP. The ATP concentration in the assay was Km ATP for the different kinases. IC50 values were determined by curve fitting of the experimental results at Thermo Fisher.

Glutathione Reactivity Assay. For this assay, 765 μl of a 3.32 mM solution of test compound in methanol was added to 765 μl of a 23.5 mM solution of reduced l-glutathione (GSH) in phosphate buffer (pH 7.4). The mixtures were stirred in a water bath held at 37°C. At specific time intervals, 200-μl aliquots were taken and analyzed by reversed-phase high-performance liquid chromatography (Supplemental). Ln(Compound)/Compound(0) was plotted against the time in minutes and linear regression analysis was performed with Excel (Microsoft, Redmond, WA). The time point at which 50% of the compound was consumed via reaction with GSH (terminal elimination half-life; t1/2) was calculated as t1/2 = Ln(2)/k, where k is the negative of the slope of the linear trend line.

Human Blood Collection and Human Peripheral Blood Mononuclear Cell Isolation. Venous blood was collected in heparin tubes from healthy human volunteers and kept at ambient temperature for no longer than 24 hours. Peripheral blood mononuclear cells (PBMCs) were isolated, this was done using the Histopaque gradient purification method (GE Healthcare, Uppsala, Sweden) and cryopreserved in 90% DMSO plus 10% fetal bovine serum (FBS).

Inhibition of BCR-Induced CD69 Surface Expression in Human B cells: Whole blood (WB) Assay. Cryopreserved PBMCs were thawed, washed, and suspended at 2 × 10⁶ cells/well in RPMI plus 10% FBS in 96-well plates. Test compounds were added to PBMCs using a 1/2 log dose titration (final concentration of 10 μM to 0.316 nM) and incubated for 2 hours at 37°C, 5% CO2. The final DMSO concentration was 0.1%. Goat anti-human immunoglobulin IgM F(ab’2) (Southern Biotech, Birmingham, AL) was added and cells were incubated for an additional 18 hours. Cells were stained with CD69-fluorescein isothiocyanate (FITC), CD19-BV421, and CD3-BV510 antibodies (BD Biosciences, San Diego, CA) for 30 minutes at 4°C, with 7-aminoactinomycin D (7-AAD) as a viability measure, followed by flow cytometry using a FACSVersus flow cytometer (BD Biosciences).

Inhibition of BCR-Induced CD69 Surface Expression in Human B cells: Whole blood (WB) Assay. 45 μl blood was diluted 1:1 in RPMI plus 1% FBS and incubated with test compound (as described above). Blood was stimulated with 10 μg/ml mouse anti-human anti-IgD (BD Biosciences) and incubated for 18 hours. Cells were stained with CD69-FITC, CD19-BV421, and CD3-BV510 (BD Biosciences) for 15 minutes at room temperature, followed by red blood cell lysis with FACS lysing solution (BD Biosciences) in a 96-deep-well plate. Cells were washed with 1 ml/well PBS plus 0.5% bovine serum albumin (BSA), pelleted, and resuspended in 200 μl/well PBS plus 0.5% BSA, followed by flow cytometry. For both PBMC and WB assays, median fluorescence intensity values for CD69 were obtained from the CD19+ CD3– B lymphocyte gate using FCExpress analysis software (De Novo Software, Glendale, CA). EC50 values were determined by curve fitting of the experimental results using Dotmatics.

Murine PD Model. Balb/c mice were dosed via oral gavage with inhibitors or vehicle and then euthanized after 1–24 hours. Extracted spleens were dissociated to obtain single-cell suspensions. Red blood cells were lysed with an ammonium chloride solution (Sigma-Aldrich, Zwijndrecht, the Netherlands). The remaining cells were washed with cold PBS and counted. An aliquot of 1 × 10⁶ cells was snap frozen (LN₂) as cell pellets for subsequent BTK target occupancy enzyme-linked immunosorbent assay (ELISA) and the remainder was used for CD69 analysis (see below).

BTK Target Occupancy ELISA. The percentage of drug-bound BTK in mouse and human samples was determined by an ELISA-based method as follows: OptiPlate 96-well plates (PerkinElmer, Waltham, MA) were coated with 125 ng/well anti-BTK antibody...
Splenocytes from drug- and vehicle-treated mice were plated at 2 x 10^6 cells/l well in a 96-well culture plate (MicroWell 96-well microplates; Nunc) cultured in Dulbecco’s modified Eagle’s medium F12 plus 10% FBS and then cultured overnight in a cell culture incubator, 37°C, 5%–7% CO₂. Serial dilutions (1/2 log) of test compounds were made in 100% DMSO and added to the Jurkat cells (final compound concentration range, 10 μM to 0.316 nM; final concentration of 0.1% DMSO). After 1-hour incubation, Jurkat cells were stimulated with anti-human CD3 and anti-human CD28 (0.1 μg/ml final concentration in the assay; BD Biosciences). The cell culture medium was harvested after 6-hour incubation after activation and was used subsequently to measure IL-2 produced by ELISA (human IL-2 CytoSets; BioSource, Frederick, MD). EC₅₀ values were determined by curve fitting of the experimental results using Dotmatics software.

Human PBMC T Cell Assay. Cryopreserved PBMCs were thawed, washed, and suspended at 1 x 10⁶ cells/well in RPMI plus 10% FBS in 96-well U-bottom polypropylene plates and rested for 1 hour at 37°C, 5% CO₂. Cells were then pretreated with a 10-point serial dilution of compounds (as described above for B cell assays). Preincubated PBMCs were transferred to 96-well round-bottom polystyrene plates coated with anti-human CD3 antibody (coated at 10 μg/ml for 2 hours at 37°C, clone UCHT-1; BD Biosciences) or in uncoated wells for controls and incubated overnight at 37°C, 5% CO₂. PBMCs were washed twice in PBMS plus 0.5% BSA and stained with CD4-Alexa Fluor 647 (clone RPA-T4) and CD8-Alexa Fluor 647 (clone RPA-T8; BD Biosciences), CD19-BV421 (clone HIB19), CD69-FITC (clone FN50; BD Biosciences), and CD25-PE-Cy7 antibodies (BD Biosciences) for 30 minutes at 4°C in the dark. After the cells were washed twice in PBS plus 0.5% BSA, 7-AAD (Life Technologies) was added and cells were analyzed on a FACSVerse flow cytometer (BD Biosciences). The percentages of CD25⁺ T cells within viable CD4⁺CD8⁺CD19⁻ T cells were determined using FCS Express software (DeNovo Software, Glendale, CA). EC₅₀ values were determined by curve fitting of the experimental results using Dotmatics software.

PK of Healthy Volunteers. Acalabrutinib was tested in an escalating-dose, safety, and PK/PD study in healthy adult volunteers. Two oral doses of 2.5, 5, 25, and 50 mg were administered 12 hours apart on a single day or as a single dose of 75 or 100 mg (study ACE-171-01). The study was performed in accordance with the ethical principles stated in the Declaration of Helsinki, U.S. Food and Drug Administration regulation 21 CFR 312 (parts 50 and 56), and International Conference on Harmonisation guidelines for good clinical practice. All subjects provided informed consent on an institutional review board–approved protocol. Acalabrutinib was administered after an overnight fast and blood samples were collected for PK analysis at predose and at 15 and 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 13, 14, 15, 16, 18, 20, 24, 36, 48, and 60 hours postdose (±5 minutes). Plasma concentrations of acalabrutinib were determined using a validated analytical liquid chromatography–tandem mass spectrometry method against a stable labeled internal standard at Basi (West Lafayette, IN) in lithium heparin plasma. The quantification range for acalabrutinib was 1–1000 ng/ml.

PK analyses were performed using noncompartmental methods with Phoenix WinNonlin (version 6.3; Pharsight Inc., Mountain View, CA) and GraphPad Prism (version 6.0 for Windows; GraphPad Software Inc., La Jolla, CA) software. The maximum observed plasma concentration (C_max) and time to reach C_max (T_max) were taken directly from the individual's data. The following PK parameters were derived from the plasma concentrations of acalabrutinib: area under the concentration-time curve (AUC) from time 0 to last quantifiable concentration (AUC₀–last), AUC from time 0 to ∞ (AUC₀–∞), C_max, T_max, t₁/₂, and terminal elimination rate constant (α). AUC₀–12, AUC₀–24, and AUC₀–∞ (where data permitted) were calculated using the linear trapezoidal method (log/linear rule). As data permitted, AUC₀–∞
was calculated as the negative of the slope of the terminal log-linear segment of the plasma concentration-time curve. \( t_{1/2} \) was calculated according to the following equation: \( t_{1/2} = \frac{0.693}{l_z} \). Oral clearance (CL/F) and volume of distribution (Vz/F) were calculated as follows: \( \text{CL/F} = \frac{\text{dose}}{\text{AUC}_{\infty}} \) and \( \text{Vz/F} = \frac{\text{Dose}}{l_z \times \text{AUC}_{\infty}} \).

**Results**

**On-Target Biochemical and Functional Characterization and Modeling of BTK Inhibitor Interactions.** Acalabrutinib (compound 1) displayed low nanomolar inhibition in the IMAP assay with an IC\(_{50}\) value of 5.1 nM. In a head-to-head comparison in the same biochemical assay, ibrutinib (compound 2) had a potency (as measured by IC\(_{50}\)) of 1.5 nM, whereas the potency of spebrutinib (compound 3) was 2.3 nM (Fig. 2). However, the inhibitory potential of spebrutinib was lower in BCR-mediated cell surface expression of CD69 in PBMCs and in the human whole blood (hWB) assay. In the latter assay, acalabrutinib (EC\(_{50}\) = 9.2 ± 4.4 nM) and ibrutinib (EC\(_{50}\) = 5.8 ± 3.0 nM) showed no statistically significant difference, whereas spebrutinib was less potent (EC\(_{50}\) = 140 nM). Inversion of the stereochemistry of acalabrutinib had a profound effect on the inhibitory potency of BTK, as demonstrated by the approximately 130-fold loss in the IMAP assay. The cell-based EC\(_{50}\) values of the \( R \)-enantiomer (compound 4) were consistent with this observation as well (592 and 1530 nM in the PBMC and hWB assays, respectively).
Figure 1 shows a model of the acalabrutinib/BTK complex that was created by docking acalabrutinib into the ATP pocket of BTK using a co-crystal structure of a reversible inhibitor/BTK complex (Protein Data Bank entry 3GEN). The model included minimization of two amino acid residues to accommodate the back-pocket filling substituent of acalabrutinib (Met449 and Leu542). This model indicates that H-bonding capabilities of the central 8-aminoimidazopyrazine moiety with Met477 and Glu475 in the hinge region are present. The 2-pyridylbenzamide shows hydrogen bonding interactions with Ser538 and Asp539.

The importance of the 2-pyridyl nitrogen was further elucidated by profiling compounds in which the 2-pyridyl nitrogen is moved to positions 3 and 4, respectively. Compounds containing 3-pyridyl (compound 5) and 4-pyridyl (compound 6) moieties were 840- and 360-fold less potent than acalabrutinib in the biochemical assay. Absence of activity was confirmed in peripheral B cells in functional assays using human PBMCs and hWB, with EC50 > 4 μM for both compounds (Fig. 2). Data generated on additional compounds highlight the relevance of the positioning of the H-bonding partners when the amide as the linker is employed (Supplemental Table 1).

We also explored the impact of (un)substituted acrylamide functions as in compounds 7, 8, and 9. Unsubstituted acrylamide compound 7 was generally 3-fold more potent in the biochemical and cell-based assays compared with acalabrutinib. However, the introduction of a methyl group on the β (as in compound 8) or α position (compound 9) of the acrylamide reduced the biochemical and cell-based potency by ≥100- and ≥900-fold, respectively. To demonstrate the relative contribution of affinity and inactivation rate, Ki and k\text{inact} values were determined for compounds 1, 2, 3, and 7 (Supplemental Table 2). The higher potency of acrylamide compound 7 compared with acalabrutinib seems to depend primarily on a faster inactivation rate (k\text{inact}), as the affinity (Ki) was relatively similar. For ibritinib, the affinity component appears to be a relative important contributor to the observed potency.

Glutathione Thiol Reactivity and Kinase Selectivity. The microenvironment of Cys481 in BTK has been reported to augment the nucleophilicity of the cysteine compared with some other cysteine-containing kinases. This presents an opportunity to improve (i.e., reduce) the electrophilicity of covalent binding BTK inhibitors. The pK\text{a} of the cysteine sulfhydryl group is directly influenced by proximal amino acids (Kortemme and Creighton, 1995; Garske et al., 2011). All TEC kinases, except ITK, contain an asparagine (Asn) residue at the i+3 position with respect to the reactive cysteine, and this results in a reported pK\text{a} of approximately 7.7 for Cys481 in BTK (Zapf et al., 2012). Intriguingly, the other cysteine-containing kinases such as EGFR, ERBB2, BLK, and JAK3 have an aspartate (Asp) in this position, which has been suggested to increase the pK\text{a} and thus lower the nucleophilicity of the sulfhydryl group. Current data suggest that the thiol pK\text{a} increases by about 0.6–1.3 log units for the Asp-containing kinases (Supplemental Table 3). Lower intrinsic electrophilicity of a covalent inhibitor appears to reduce the likelihood of covalent binding to off-target cysteines with a lower nucleophilicity and favorably affects kinase selectivity within the kinase subset with an Asp in the i+3 position while preserving potency for BTK.

To further substantiate whether the relative reactivity of the electrophilic moieties could impact the BTK potency and the overall kinase selectivity profile, the inhibitors were reacted with GSH in a semiphysiologic setting. Acalabrutinib has a butynamide moiety, which contributes to a slower conversion of the parent, with a t1/2 of 5.5 hours (Fig. 2). In contrast, the acrylamide-containing compounds ibritinib and spebrutinib were more rapidly consumed than acalabrutinib, with average t1/2 values of 2 and 1 hours, respectively. Intriguingly, compound 7 displayed a much faster turnover than acrylamides ibritinib and spebrutinib. The closer proximity of the electrophile in compound 7 to the electron-deficient central heteroaryl imidazopyrazine moiety could augment the electrophilicity and may explain the lower t1/2 average of 0.6 hours. Methyl compounds 8 and 9 lose the capacity to react with GSH, which suggests that the degree of BTK inhibition observed could be due to reversible binding (Fig. 2). The observation that compound 8 still displayed some residual activity suggests that steric hindrance in proximity of Cys481 impacts the binding potential, rather than the relative electrophilicity of the reactive group per se.

Proﬁling of the clinical BTK inhibitors and compound 7 on the cysteine kinase panel distinguishes acalabrutinib from the acrylamide compounds in terms of selectivity. All kinases with an Asp in the i+3 position were not sensitive to acalabrutinib, and the inhibition of TEC, BMX, and TXK kinases was lower than for any of the acrylamide compounds. A direct comparison of the IC50 values of acalabrutinib and acrylamide-containing compound 7 revealed the influence of the warhead choice on the cysteine kinase selectivity profile (Table 2). In this data set, ERBB4 is an outlier, as this is the only kinase that has a glutamate (Glu) in the i+3 position. Although the predicted cysteine pK\text{a} is on par with Asp in this position, the inhibition of ERBB4 may be governed to a lesser extent by the electrophilic potential, rather than the relative electrophilicity of the reactive group per se.

### Table 2

IC50 determination on cysteine kinases with a cysteine in the same position as Cys481 in BTK

| Kinase | i+3 Residue | IC50 1 | IC50 2 | IC50 3 | IC50 7 |
|--------|-------------|--------|--------|--------|--------|
| BTK    | Asn         | 5.1 ± 1.0 | 1.5 ± 0.2 | 2.3 ± 0.5 | 1.6 ± 0.2 |
| TEC    | Asn         | 126 ± 11  | 10 ± 2  | 16 ± 4  | 41 ± 3  |
| ITK    | Asp >1000   | 4.9 ± 1.2 | 24 ± 2  | 85 ± 2  |
| BMX    | Asn <46 ± 12 | 0.8 ± 0.1 | 1.6 ± 0.4 | 3.3 ± 0.4 |
| TXK    | Asn 368 ± 141 | 2.0 ± 0.3 | 9.1 ± 2.7 | 7.6 ± 2.4 |
| EGFR   | Asp >1000   | 5.3 ± 1.3 | 199 ± 35 | 20 ± 5  |
| ERBB2  | Asp <1000   | 6.4 ± 1.8 | >1000  | 13 ± 3  |
| ERBB4  | Glu 16 ± 5  | 3.4 ± 1.4 | 49 ± 12 | 5.3 ± 0.5 |
| BLK    | Asp >1000   | 0.1 ± 0.0 | 131 ± 27 | 19 ± 4  |
| JAK3   | Asp >1000   | 32 ± 15  | 5.4 ± 1.1 | >1000  |

**Note:** The overall kinase selectivity profile of acalabrutinib was evaluated on a panel of 456 human kinases (KINOMEscan at Thermo Fisher). Results are mean ± S.D. of at least three independent experiments.
DiscoverX, Fremont, CA). Of these kinases, 395 are non-mutant protein kinases. Our results demonstrate that acalabrutinib is the most selective BTK inhibitor of the three compounds profiled (Fig. 3). For acalabrutinib, only 1.5% of the nonmutant protein kinases were inhibited ≥65% at 1 μM. For ibrutinib and spebrutinib, 8.9% and 7.6%, respectively, of the nonmutant protein kinases were inhibited ≥65% at 1 μM. Interestingly, strong inhibition by ibrutinib was observed for all kinases belonging to the SRC-family kinases, which is in line with earlier published results (Honigberg et al., 2010) and our own data (Byrd et al., 2016). Spebrutinib showed a more scattered inhibition over the kinase phylogenetic tree. Evaluation of SRC-family kinase inhibition confirmed that acalabrutinib did not inhibit any member (IC50 values all exceeding 1 μM), whereas ibrutinib demonstrated single- or double-digit nanomolar inhibition on all members tested (Supplemental Table 4).

Off-Target Cellular Activities of BTK Inhibitors. The functional relevance of the differences in the observed biochemical inhibition of non-BTK kinases by acalabrutinib, ibrutinib, spebrutinib, and compound 7 was explored in specific cell lines. EGFR inhibition of selected BTK inhibitors was tested in two EGFR-expressing human tumor cell lines: an epidermoid carcinoma (A431) cell line (Table 3) and a bladder carcinoma (HT-1376) cell line (Supplemental Fig. 1). Both cell lines gave similar EC50 values for the tested compounds on EGF-induced EGFR phosphorylation. Acalabrutinib showed no or only minimal inhibition up to a concentration of 10 μM. Results with compound 7 suggest that this is due to the electrophile switch from acrylamide to butynamide. Spebrutinib inhibited EGF-induced EGFR phosphorylation with an EC50 of 4.7 μM, which suggests that the reactivity of electrophile is not the only parameter relevant for kinase selectivity. Ibrutinib inhibited
**TABLE 3**

| Compound | EC50 EC50 | Anti-CD3/CD28–Induced IL-2 Production in Jurkat Cells≤ | Anti-CD3–Induced CD25 Expression in PBMC≤ |
|----------|-----------|---------------------------------------------------|-----------------------------------------|
| 1        | >10,000   | 10,000                                            | 10,000                                   |
| 2        | 71 ± 14   | 99 ± 17                                           | 257 ± 71                                 |
| 3        | 4680 ± 720| 150 ± 22                                          | 575 ± 60                                 |
| 7        | 327 ± 2   | 911 ± 61                                          | 2600 ± 956                               |

≤Results are the mean ± S.D. of two independent experiments.

EGF-induced EGFR phosphorylation in A431 cells, with an EC50 of 71 nM.

The compounds were also evaluated in T cell functional assays. First, the compounds were profiled in anti-CD3/CD28–induced IL-2 production in Jurkat T cells, using a Jurkat E6 T cell clone with high IL-2 expression after stimulation. Ibrutinib and spebrutinib showed inhibition of anti-CD3/anti-CD28–induced IL-2 production, with EC50 values of 99 and 150 nM, respectively (Table 3). Also in line with the biochemical data on ITK, compound 7 was less potent in the Jurkat T cell assay than ibrutinib and spebrutinib. Acalabrutinib displayed an EC50 > 10 μM in the Jurkat T cell assay, which is expected given its biochemical selectivity over T cell kinases ITK and TXK. In addition, effects in PBMCs were studied by measuring the inhibition of anti-CD3–induced CD25 cell surface expression on human peripheral T cells. The order of inhibitory potential of the tested compounds followed the ranking as determined in Jurkat cells, with ibrutinib being the most potent (EC50 = 257 nM) and acalabrutinib being the least potent (EC50 > 10 μM) (Table 3).

**Preclinical PD Model in Mice.** To investigate potency in vivo, mice were treated with oral doses ranging from 0.1 to 30 mg/kg acalabrutinib, ibrutinib, or spebrutinib or with vehicle. Three hours after dosing, spleens were extracted and single-cell suspensions of splenocytes were prepared. The splenocytes were stimulated with anti-IgM for 18 h, followed by analysis of CD69 expression by flow cytometry gated on CD19+ B cells (Fig. 4). ED50 determinations showed that acalabrutinib was the most potent BTK inhibitor in vivo (1.3 mg/kg), followed by ibrutinib (2.9 mg/kg) and spebrutinib (20 mg/kg). Because of the covalent nature of binding, BTK inhibitors have been shown to have a prolonged PD effect even in the presence of circulating free BTK. These return rates were 2.0% ± 0.2% and 1.7% ± 0.1% per hour, respectively.

**PK/PD in Healthy Volunteers.** The PK properties and safety of acalabrutinib were evaluated in a sequential dose-escalation study in healthy adult volunteers (six per group) after oral administration of two doses of 2.5, 5, 25, or 50 mg given 12 hours apart on a single day and a single dose of either 75 or 100 mg. Acalabrutinib was rapidly absorbed, with median time to maximum plasma concentration (Tmax) values between 0.5 and 1.0 hours for all dose cohorts, independent of dose level (Supplemental Fig. 2; Supplemental Table 5). The increase in mean Cmax was greater than dose proportional from 5 to 25 mg. However, between 2.5–5.0, 25–50, and 50–100 mg, the increases in mean Cmax were close to dose proportional. The mean values of AUC(0–24), AUC(0–24), and AUC(0–∞) increased in a dose-proportional manner based on the increases of the total dose administered (Fig. 5A). Linear regression analysis of the natural log (ln) transformed AUC(0–24) and AUC(0–∞) relative to the ln transformed dose administered, indicated that the increases in AUC relative to the increases in dose administered were linear. Rapid elimination was observed, with mean t1/2 values ranging from 0.88 to 2.1 hours in cohorts 1–5. The mean calculated Vz/F values ranged from 165 to 219 l/h and appeared to be independent of the dose administered. Vz/F values ranged from 232 to 612 liters and also appeared to be independent of the dose administered.

Of 59 enrolled subjects, 16 (27%) reported one or more adverse events during the study. All adverse events were grade 1 or 2. No serious adverse events occurred in the study. Of the adverse events reported, three (constipation, somnolence, and feeling cold) were assessed as related to acalabrutinib. No study drug–related adverse events led to discontinuation from the study. No effect of acalabrutinib was observed on any laboratory parameters (i.e., hematology, serum chemistry, urinalysis, cardiac troponin I, and C-reactive protein). No effect was
Fig. 4. (A) In vivo potency. Mice (five per group) were given an oral dose of acalabrutinib, ibrutinib, spebrutinib, or vehicle over a concentration range (x-axis). After 3 hours, spleens were extracted and splenocytes were stimulated with anti-IgM for 18 hours, followed by CD69 expression analysis by flow cytometry gated on CD19+ B cells. The CD69 median fluorescent intensity values were normalized as a percentage of the vehicle control group and the mean average and S.E.M. were plotted for all mice in each dose cohort. (B) Return of function. Mice (five per group) received a single oral 25 mg/kg dose of acalabrutinib, ibrutinib, spebrutinib, or vehicle. Spleens were extracted 3, 6, 12, 18, or 24 hours after dosing and single-cell suspensions were made. Splenocytes were immediately cultured with anti-IgM for 18 hours, followed by CD69 surface expression measurement by flow cytometry as in (A). Data show CD69 expression for each mouse normalized as a percentage of the vehicle control group. Data presented are expansions from Herman et al. (2017). (C) BTK target occupancy was measured in the mouse splenocyte samples from the experiment described in (B). (D) Structure of the target occupancy probe ACP-4016 (compound 10). Cmpd, compound.
observed of acalabrutinib on physical examinations, vital signs, or electrocardiography parameters. The PD of acalabrutinib was evaluated using the BTK occupancy assay and measuring the inhibition of CD69 expression on B cells after ex vivo BCR stimulation. Both PD readouts were dose dependent, with a plateau observed at the 75- and 100-mg dose levels, 3 hours after acalabrutinib administration. At this time point, the degree of BTK median occupancy was around 99% for the 75- and 100-mg doses (Fig. 5B). This correlated with near complete inhibition for CD69 (Fig. 5C) for the same doses and time point. However, only the 100-mg cohort maintained high BTK median occupancy and high BCR functional inhibition over time (Fig. 5D). At 12 hours, the median occupancy was 99% and the median CD69 inhibition was 95%, whereas these parameters were 90% and 84% at 24 hours, respectively. CD86 expression levels were also determined in parallel and essentially matched the inhibition of CD69 expression (data not shown).

**Discussion**

Acalabrutinib was identified as a BTK inhibitor with a differentiated kinase selectivity profile compared with other BTK inhibitors in development. Key structural components of acalabrutinib include a 2-pyridylbenzamide moiety and the electrophilic 2-butynamide moiety that is involved in covalent binding to Cys481. The proximal positioning of the 2-butynamide moiety to the electron-deficient (and thus electron-withdrawing) imidazopyrazine core may help to reactivated this otherwise
fairly inert functionality. The potency difference of the enantiomeric pair (compare acalabrutinib and compound 4) showed that the activity primarily resides in the S-enantiomer, suggesting better positioning of the butynamide moiety. As demonstrated in the GSH assay, acalabrutinib displayed lower reactivity than acrylamides ibrutinib, spebrutinib, and compound 7. This may help to minimize inhibition of off-target cysteine kinases that exhibit higher cysteine $pK_a$ values than that for Cys481 in BTK. Indeed, acalabrutinib is the most selective with regard to inhibition of TEC-, EGFR-, and SRC-family kinases. The correlation of biochemical off-target inhibition and functional consequences in selected cell lines was confirmed for different kinases.

Inhibitors of the EGFR signaling pathway cause skin rash and diarrhea, and these toxicities are believed to be "class effects" (Lynch et al., 2007; Dy and Adjei, 2013). With respect to the inhibitory potential for EGFR, the rank order of compounds was identical in biochemical and cellular settings, with acalabrutinib showing a lack of functional inhibitory effects ($EC_{50} > 10 \mu M$). The events of diarrhea reported during acalabrutinib treatment of patients with CLL (grades 1 to 2, 38%; all grades, 39%) have been generally mild (Byrd et al., 2016). Given the observed exposure levels of acalabrutinib after a single oral dose of 100 mg (580 ± 150 ng/ml) and the absence of effects on phospho-EGFR inhibition in two relevant cell lines at these concentrations, we do not expect to see EGFR-mediated adverse events for acalabrutinib.

ITK signaling in Jurkat cells and in primary human peripheral T cells correlated with the biochemical IMAP data. The drug concentrations needed to inhibit IL-2 production in Jurkat cells and modulation of human peripheral T cells may well be achieved in patients treated with ibrutinib or spebrutinib (Dubovsky et al., 2013; Evans et al., 2013) and therefore may bear physiologic relevance. Indeed, ibrutinib is a reported irreversible covalent ITK inhibitor with confirmed occupancy on this kinase in patients with CLL (Dubovsky et al., 2013). Treatment with ibrutinib reduced the number of Th17 T cells as a percentage of the total T cell population in patients with CLL, as well as Th17 development from mouse naive CD4 + T cells. The mouse observations are in line with data reported for ITK$^{-/-}$ mice, in which a shift in the balance from Th17 to regulatory T cells was observed (Gomez-Rodriguez et al., 2014). The same authors reported that this effect is even more pronounced in ITK/ITK$^{-/-}$ mice (Gomez-Rodriguez et al., 2011), indicating redundancy between ITK and TXK. Since ibrutinib inhibited both ITK and TXK in the low nanomolar range in the biochemical assays, the effects of ibrutinib on T cell differentiation most likely mimic the double-knockout phenotype. ITK is also expressed in natural killer (NK) cells (Khurana et al., 2007), and inhibition thereof has been reported to decrease the antibody-dependent cellular cytotoxicity function of NK cells (Kohrt et al., 2014). It was reported that ibrutinib inhibited both rituximab- and trastuzumab-induced NK cell cytokine secretion and lysis in vitro in a dose-dependent manner (0.1 and 1 $\mu M$), whereas acalabrutinib did not show any effects at 1 $\mu M$ (Rajasekaran et al., 2014). This indicates that acalabrutinib is associated with a reduced risk of affecting antibody-dependent cellular cytotoxicity–mediated therapies.

An increased incidence in severe hemorrhage was reported in patients treated with ibrutinib and has been attributed to the effect of ibrutinib on several distinct signaling pathways (Byrd et al., 2015; Wang et al., 2015; Shatzel et al., 2017). Therefore, patients receiving ibrutinib are monitored to reduce the potential risk for bleeding. Although the role of BTK on collagen-induced platelet aggregation has been well described, there is no general increase of bleeding risk in patients with X-linked agammaglobulinemia lacking functional BTK (Quek et al., 1998; Winkelstein et al., 2006), suggesting that BTK inhibition alone is likely not responsible for increased bleeding risk. In platelets, the downstream signaling of several receptors on platelets, including the platelet collagen receptor glycoprotein VI and C-type lectin-like receptor 2, is mediated by BTK and TEC (Shatzel et al., 2017). Earlier, we reported on differences in platelet aggregation using platelets from patients treated with acalabrutinib or ibrutinib (Byrd et al., 2016). In an in vivo thrombus formation model, diminished platelet reactivity was observed in samples from patients treated with ibrutinib, whereas platelets from acalabrutinib-treated patients showed similar reactivity to those derived from non-treated healthy controls. Because TEC kinase phosphorylation is highly dependent on platelet aggregation (Hamazaki et al., 1998; Atkinson et al., 2003), the level of TEC inhibition may govern the bleeding risk. The relative biochemical $IC_{50}$ values for TEC of acalabrutinib (126 nM) and ibrutinib (10 nM) may well contribute to the observed differences in the above model. In addition, inhibition of SRC-family kinases by ibrutinib may play a role in the observed bleeding incidence in ibrutinib-treated patients through modulation of fibrinogen- and von Willebrand factor–induced platelet activation (Séverin et al., 2012; Senis et al., 2014). Regulation of SRC-mediated platelet activation may be anticipated at exposure levels observed in patients that are treated with ibrutinib. For instance, Patel et al. (2017) reported that ibrutinib demonstrated potent inhibition of phosphorylation of SRC family members LCK and SRC in T cells, with an $EC_{50}$ of <0.2 $\mu M$, whereas the $EC_{50}$ for acalabrutinib was not reached at 10 $\mu M$. Again, these data correspond well with the nanomolar inhibition by ibrutinib for both SRC and LCK. Taken together, these observations indicate that effects of ibrutinib on bleeding could be multifactorial. The improved selectivity profile of acalabrutinib for BTK versus TEC and SRC-family kinases may prove advantageous in this regard.

Overall, the biochemical potency of all compounds tested for BTK activity traced well with the inhibitory potential of marker CD69 in our PBMC and hWB assays, except for spebrutinib. For instance, the potency of BTK-mediated inhibition of peripheral B cell function in hWB was approximately 15-fold lower for spebrutinib than for acalabrutinib and ibrutinib. This suggests that plasma proteins or other components of hWB (e.g., red blood cells, platelets, or neutrophils) may contribute to a lower free fraction of spebrutinib that is available for BTK inhibition. The in vivo potency data generated in the mouse PD model mirrored the cellular data generated, except that acalabrutinib showed better potency than ibrutinib in vivo. With spebrutinib, efficacy could be obtained at higher dosages, but potency was inferior to acalabrutinib and ibrutinib. Evaluation of return of free BTK and return of B cell function in mice demonstrated that the return rate is independent of the type of BTK inhibitor tested. Hence, the de novo synthesis rate of BTK is the primary driver for the loss of PD effect in a single dose setting.
In human healthy subjects, acalabrutinib is an orally bioavailable BTK inhibitor with fast absorption, dose-proportional PK, and a short half-life in the systemic circulation. Despite the short half-life, acalabrutinib had a pronounced on-target impact in peripheral blood B cells that was dose dependent. Complete BTK occupancy was observed 3 and 12 hours after a single 100-mg dose, indicating that a saturating concentration was achieved that resulted in near complete inhibition of a BCR-induced functional response (i.e., CD69 expression). Both measures remained high for 24 hours. Therefore, covalent modification of BTK by acalabrutinib prolonged target occupancy and PD that extend beyond the relatively short plasma half-life in healthy volunteers. In patient populations with more rapidly proliferating B cells, we anticipate an increased de novo synthesis rate of BTK, suggesting that more frequent dosing may be required to achieve optimal BTK inhibition. Indeed, a 100-mg twice-daily dose in patients with CLL showed a higher median BTK occupancy, with less variability at trough, than the 100- and 250-mg/d cohorts (Byrd et al., 2016). This illustrates that maximal target coverage can be achieved with twice-daily dosing, which we believe is advantageous for optimal treatment across patient populations with B cell malignancies. In conclusion, monitoring structure-reactivity relationships may help to mitigate the risk for off-target adverse events related to reactivity of the electrophile (Barf and Kaptein, 2012). Low electrophilicity is an important feature to consider to progress the most suitable covalent inhibitor candidates through the pipeline. The use of a straightforward GSH assay to assess the likelihood and the kinetics of covalent binding revealed a difference in reactivity between compounds containing butyramide and acrylamide moieties. We believe that the lower electrophilicity of acalabrutinib along with the higher nucleophilicity of Cys481 in BTK contributes to the observed selectivity profile, which may reduce off-target-mediated adverse events. In combination with the improved in vivo potency, acalabrutinib appears to have a differentiated preclinical profile from ibrutinib and spebrutinib. Selective covalent BTK probe 10 helped to confirm the degree of BTK occupancy and engagement by acalabrutinib in preclinical and clinical settings. Acalabrutinib is a rapidly absorbed covalent BTK inhibitor with a short half-life, yet it reaches full target occupancy at a single oral dose of 100 mg in healthy human subjects. Clinical evaluation of acalabrutinib in multiple B cell malignancies, solid tumors, and selected autoimmune indications is currently in progress.

Acknowledgments

The authors thank Anouk de Jong for performing the PBMC T cell assays, Tim Ingalliera for preparing the in vivo formulations for the mouse PD experiments, Gerjan de Bruin for analysis of the $K_i$ and $k_{inaact}$ data, and Greg Slatter for the discussion on the human PK/PD data. BioAssay Research BV is acknowledged for the pH$_2$ modeling of kinase cysteines. Final versions of the figures were created by Cognition Studios. This article reflects the views of the authors on some of the research and data regarding acalabrutinib. This research has spanned many years and is ongoing. This article does not attempt to address exhaustively every aspect and detail of that research. All authors are employees of or consultants to and are shareholders of Acerta Pharma BV.

Acalabrutinib: A Differentiated Covalent BTK Inhibitor

Authorship Contributions

Participated in research design: Barf, Covey, Izumi, Gulrajani, Mittag, Pearson, Ulrich, Kaptein.
Conducted experiments: Barf, van de Kar, Gulrajani, van Lith, van Hoek, de Zwart, Mittag, Demont, Verkaik, Krantz.
Performed data analysis: Barf, Covey, Izumi, van de Kar, Gulrajani, van Lith, van Hoek, de Zwart, Mittag, Demont, Verkaik, Krantz, Pearson, Kaptein.
Wrote or contributed to the writing of the manuscript: Barf, Covey, Izumi, Pearson, Kaptein.

References

Akherson BT, Ellmier M, and Watson SP (2003) Tec regulates platelet activation by GPVI in the absence of Btk. Blood 102:3592–3599.
Barf T and Kaptein A (2012) Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem 55:6245–6262.
Bender AT, Pereira A, Fu K, Samy E, Wu Y, Liu-Bujalski I, Caldwell R, Chen Y-Y, Tian H, Morandi F, et al. (2016) Btk inhibition treats TLR7/8FN driven murine lupus. Clin Immunol 164:65–77.
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharmann JP, Schreeder MT, Barr PM, Funk FK, Miller TP, Burdzy JA, et al. (2016) Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica 101:285–286.
Byrd JC, Furlan BR, Coustan SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, et al. (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2473–2482.
Byrd JC, Harrington B, O’Brien S, Jones JA, Schuch A, Devereux S, Chaves J, Wierda WG, Awan PT, Brown JB, et al. (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:523–532.
Byrd JC, O’Brien S, and James DP (2013) Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:1278–1279.
de Weers M, Verschueren MC, Kraamke MM, Mensink RG, Schuurman RK, van Dungan JN, and Hendriks BW (1995) The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages to progress the most suitable covalent inhibitor candidates. J Immunol 23:3109–3116.
Doherty SI, Bedworth WA, Natalajaran G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu T-M, Chang BY, Larkin KM, et al. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 125:2539–2549.
Dy GK and Adjei AA (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 63:249–279.
Ellmier W, Abramova A, and Schebestas A (2011) Tec family kinases: regulation of receptor-induced signaling and phagocytosis. J Immunol 186:7777–7783.
Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Dy GK and Adjei AA (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 63:249–279.
Garske AL, Peters U, Cortesi AT, Perez JL, and Shokat KM (2011) Chemical genetic strategies for targeting genes based on covalent complementarity. Proc Natl Acad Sci USA 108:15406–15405.
Gomez-Rodriguez J, Kraus ZJ, and Schwartzberg PL (2011) Tec family kinases IkB and Btk/Tekk in T lymphocytes: cross-regulation of cytokine production and T-cell fate. Eur J Immunol 41:2780–2788.
Gomez-Rodriguez J, Wohlfert EA, Handor R, Meylan F, Wu JZ, Anderson SM, Kirby MR, Belkaid Y, and Schwartzberg PL (2014) Ik-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med 210:529–543.
Grenningloh R (2016) Discovery of the highly specific BTK inhibitor M2951 and pharmacological modeling of BTK occupancy versus efficacy in BA and SLE models. 14th Annual Discovery on Target; 2016 Sep 19–22; Boston, MA.
Hamaa Z, Kojima N, Mano H, Nagata Y, Tokodoko K, Abe T, and Nagasawa T (1998) Tec is involved in G protein-coupled receptor- and integrin-mediated signaling in human blood platelets. Oncogene 16:2773–2779.
Hendriks RW, Yuvaraj S, and Kil LP (2014) Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14:219–232.
Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith L, McClanahan F, Harrington BK, et al. (2017) The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res 23:2931–2941.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13097–13080.
Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CJ, and Cybulsky MI (2015) Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol 191:289–298.
Katz FE, Lovering RC, Bradley LA, Ripley KP, Brown D, Cotter F, Chessells JM, Levinsky RJ, and Kinnon C (1994) Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. Leukemia.8:574–577.
Khurana D, Arneson LN, Schoon RA, Dick CJ, and Leibson PF (2007) Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase ikB. J Immunol 178:3575–3582.
Kortemme T and Creighton TE (1995) Ionisation of cysteine residues at the termini
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X,
Buggy JJ, Mathussamy N, Levy R, et al. (2014) Ibrutinib antagonizes rituximab-
dependent NK cell-mediated cytotoxicity. Blood 124:1857–1860.
Kortemme T and Creighton TE (1995) Ionisation of cysteine residues at the termini
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X,
Buggy JJ, Mathussamy N, Levy R, et al. (2014) Ibrutinib antagonizes rituximab-
dependent NK cell-mediated cytotoxicity. Blood 124:1857–1860.

Lynch TJ, Jr. Kim ES, Eaby B, Garey J, West DP, and Lacouture ME (2007) Epi-
dermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolv-
ing paradigm in clinical management. Oncologist 12:610–621.
Norman P (2016) Investigational Bruton’s tyrosine kinase inhibitors for the treat-
ment of rheumatoid arthritis. Exp Opin Invest Drugs 25:891–899.
O’Brien S, Furman RR, Coutre SE, Sharan JA, Burger JA, Blum KA, Grant B,
Richards DA, Coleman M, Wierda WG, et al. (2014) Ibrutinib as initial ther-
apy for elderly patients with chronic lymphocytic leukemia or small lymph-
phocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol
15:48–58.
Pan Z, Scheeren H, Li S-J, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV,
Sweeney MD, Scott KCK, Grothaus PG, et al. (2007) Discovery of selective irre-
versible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2:58–61.
Park JK, Byun J-Y, Park JA, Kim Y-I, Lee YJ, Oh Ji, Jung SY, Kim YH, Song YW,
Son J, et al. (2016) HM71224, a novel Bruton’s tyrosine kinase inhibitor, sup-
presses B cell and monocyte activation and ameliorates arthritis in a mouse model:
19:91.
Patel V, Balakrishnan K, Bihikova E, Ayres M, Keating MJ, Wierda WG, and Gandhi
V (2017) Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor,
with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res 23:
3734–3743.
Ponader S and Burger JA (2014) Bruton’s tyrosine kinase: from X-linked agamma-
globulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol
32:1830–1839.
Quak LS, Bolen J, and Watson SP (1998) A role for Bruton’s tyrosine kinase (Btk) in
platelet activation by collagen. Curr Biol 8:1137–1140.
Rajasekaran N, Sadaram M, Hebb J, Sagiv-Barfi I, Ambulkar S, Rajapaksa A, Chang S,
Chester C, Wailer E, Wang L, et al. (2013) Three BTK-specific inhibitors, in contrast
to ibrutinib, do not antagonize rituximab-dependent NK cell-mediated cytotoxicity.
Blood 124:3118.
Severin S, Nash CA, Mori J, Zhao Y, Abram C, Lowell CA, Senis YA, and Watson SP
(2012) Distinct and overlapping functional roles of Src family kinases in mouse
platelets. J Thromb Haemost 10:1631–1645.
Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, and DeLoughery TG (2017)
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction
strategies. J Thromb Haemost 15:835–847.
Smith PF, Krishnanaraj J, Nunn PA, Hill RJ, Karr D, Tam D, Masjiedizadeh M, and
Gourlay SG (2015) A phase 1 clinical trial of PB1008, an oral, reversible, covalent
BTK inhibitor demonstrates clinical safety and therapeutic levels of BTK occupancy
without sustained systemic exposure (Abstract). Ann Rheum Dis 74 (Suppl 2):742.
Tom C, Grigg AP, Opat S, Ku M, Gilberson M, Anderson MA, Seymour JF, Ritchie
DS, Dicrolet C, Dimovski E, et al. (2015) The BTK inhibitor, Bgb-3111, is safe,
tolerable, and highly active in patients with relapsed/refractory B-cell malignan-
cies: initial report of a phase I first-in-human trial. Blood 120:832.
Walter HS, Rule SA, Dyer MJS, Karlén L, Jones C, Cazin B, Quittet P, Shah N,
Hutchinson CV, Honda H, et al. (2016) A phase 1 clinical trial of the selective BTK
inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Blood 127:411–419.
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH,
Romagnuolo JR, Williams ME, et al. (2015) Long-term follow-up of MCL patients treated
with single-agent ibrutinib: updated safety and efficacy results. Blood 126:739–745.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH,
Romagnuolo JR, Williams ME, et al. (2013) Targeting BTK with ibrutinib in rel-
apsed or refractory mantle-cell lymphoma. N Engl J Med 369:507–516.
Whang JA and Chang BY (2014) Bruton’s tyrosine kinase inhibitors for the treat-
ment of rheumatoid arthritis. Drug Discov Today 19:1290–1294.
Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burke AS,
Conley MC, Cunningham-Rundles C, and Ochs HD (2006) X-linked agammaglob-
ulinemia: report on a United States registry of 201 patients. Medicine (Baltimore)
85:193–202.
Zapf CW, Gerstenberger BS, Xing L, Limburg DC, Anderson DR, Caspers N, Han S,
Aulabah K, Kurumbail R, Shahy S, et al. (2012) Covalent inhibitors of interleukin-
2-inducible T cell kinase (itk) with nanomolar potency in a whole-blood
assay. J Med Chem 55:10047–10063.

Address correspondence to: Tjeerd Barf, Acerta Pharma BV, Kloosterstraat
9, 5349 AB Oss, The Netherlands. E-mail: t.barf@acerta-pharma.com
Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile

Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont, Saskia Verkaik, Fanny Krantz, Paul G. Pearson, Roger Ulrich and Allard Kaptein

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
SUPPLEMENTAL INFORMATION

Table S1: Chemical structures of test compounds and associated biochemical and cell-based data.

![Chemical Structures](image)

| Cmpd | BTK (IMAP) IC₅₀ (nM) | PBMC (CD69) EC₅₀ (nM) |
|------|-----------------------|------------------------|
| 10   | 2.2 ± 0.6*            | --                     |
| 11   | 2.9 ± 0.3             | 5.5 ± 2.0              |
| 12   | 4.0 ± 2.0             | 8.5 ± 1.4              |
| 13   | 3,997 ± 2,090         | > 10,000               |
| 14   | 458 ± 70              | 956 ± 294              |
| 15   | > 10,000              | > 10,000               |
| 16   | 4,950 ± 1,645         | ~ 10,000               |

Results are average ± SD of three independent experiments. * N = 4.
BTK-WT LanthaScreen™ TR-FRET binding assay to determine inhibition kinetics.

Inhibitory activity on BTK wildtype (BTK-WT) was measured using the LanthaScreen™ assay technology from Thermo Fisher according to manufacturer’s protocol, with a final concentration of 5 nM of BTK-WT (custom made at Genscript) and 2 nM Eu-anti-GST antibody (Invitrogen). Serial dilutions log10 from 1 mM to 0.316 nM of test compounds were made in 100% DMSO and then diluted 33-fold in Kinase buffer (50 mM Hepes pH 7.5 + 10 mM MgCl₂ + 1 mM EGTA + 0.01% Brij-35) and 3-fold in the final assay mixture. Final compound concentration in the assay ranged from 10 µM to 0.00316 nM, with 1% DMSO final concentration in assay. Test compounds, enzyme/antibody mix, and Tracer 236 (Invitrogen, final concentration 30 nM) were added together and incubated at room temperature in the dark. At different incubation times (ranging from 1 to 60 minutes), the TR-FRET signal was read at 615 nm and 665 nm. The ratio 665/615 was used to calculate values expressed as percentage of the difference in readout (S/N) of the controls with and without Tracer. IC₅₀ values for each timepoint were determined by curve fitting of the experimental results in Prism, and were used to determine Kᵣ, kᵢₙᵃｃᵉᵗ, and kᵢₙᵃᶜᵉᵗ/Kᵣ according to the method described by Krippendorf et al (1)

Table S2: Inhibition kinetics parameters for compounds 1, 2, 3 and 7 from BTK-WT LanthaScreen™ TR-FRET binding assay

| Compound | Kᵣ (nM) | kᵢₙᵃᶜᵉᵗ (s⁻¹) | kᵢₙᵃᶜᵉᵗ/Kᵣ (M⁻¹s⁻¹) |
|----------|--------|----------------|------------------------|
| 1        | 181 ± 14 | 0.0056 ± 0.0025 | 3.11 x 10⁴ ± 1.48 x 10⁴ |
| 2        | 54.2 ± 48.6 | 0.027 ± 0.025 | 4.77 x 10⁵ ± 1.67 x 10⁵ |
| 3        | 174 ± 83 | 0.014 ± 0.0048 | 8.28 x 10⁴ ± 1.68 x 10⁴ |
| 7        | 270 ± 19 | 0.021 ± 0.0019 | 7.64 x 10⁴ ± 4.20 x 10³ |

Results are average ± SD of 4 independent experiments.
**Cysteine pKₐ predictions.** Propka (2) is a program to empirically calculate the pKₐ of ionisable protein residues, taking into account Coulombic, intrinsic electrostatic and desolvation terms, adjusted for how buried/exposed contributing residues are. Propka version 3.1 calculations were performed on all human structures from the MOE (3) Protein kinase database of the kinase in question. The MOE Protein kinase dataset contains 5275 non-redundant kinase chains from the pdb. Searches were performed to retrieve kinases as shown below. Ligands were removed and the structures subjected to pKₐ prediction by Propka 3.1. The small number of structures where Propka failed to provide a pKₐ prediction were ignored. Means and standard deviations of results are shown below in Table S3 below:

| Kinase | i+3 residue | No. of Structures | No. of Successful predictions | Mean Propka pKₐ ± SD | ΔpKₐ vs BTK |
|--------|-------------|--------------------|-------------------------------|----------------------|------------|
| BTK    | Asn         | 29                 | 24                            | 9.59 ± 0.61          | --         |
| TEC    | Asn         | -                  | -                             | 9.41ᵇ)               | - 0.18     |
| ITK    | Asp         | 56                 | 49                            | 10.16 ± 0.73         | + 0.57     |
| BMX    | Asn         | 3                  | 3                             | 9.48 ± 0.31          | - 0.11     |
| TXK    | Asn         | -                  | -                             | 9.55ᵇ)               | - 0.04     |
| EGFR   | Asp         | 124                | 121                           | 10.62 ± 0.49         | + 1.03     |
| ERBB2  | Asp         | 6                  | 6                             | 10.79 ± 0.15         | + 1.20     |
| ERBB4  | Glu         | 9                  | 8                             | 10.30 ± 0.47         | + 0.71     |
| BLK    | Asp         | -                  | -                             | 10.92ᵇ)              | + 1.33     |
| JAK3   | Asp         | 21                 | 20                            | 10.27 ± 0.50         | + 0.68     |

ᵃ) Non redundant chains in MOE protein Kinase database. Structures with modified cysteines where the Cys is oxidized to a sulphonic acid (OCS) were rejected. Cysteines with covalently bonded ligands were included, though the ligands were removed. ᵇ) Homology modelling experiments using the standard homology building macros were performed using both the A and B chains of 1k2P, the only apo BTK structure, as templates. Side chain conformations of the binding site Cys and i+3 residue were taken from the template and maintained to ensure a match with observed conformations. pKₐ presented is the calculated average of the A and B chains.
Table S4: IC$_{50}$ determination of 1, 2 and 3 on SRC family kinases. Kinase activity was measured at Thermo Fisher using the Z'-LYTE assay.

| Kinase | 1 (nM) | 2 (nM) | 3 (nM) |
|--------|--------|--------|--------|
| FGR    | >1,000 | 3.3 ± 1.1 | 348 ± 93 |
| FYN    | >1,000 | 29 ± 0 | >1,000 |
| HCK    | >1,000 | 29 ± 0 | >1,000 |
| LCK    | >1,000 | 6.3 ± 1.3 | >1,000 |
| LYN    | >1,000 | 20 ± 1 | >1,000 |
| SRC    | >1,000 | 19 ± 1 | 699 ± 302 |
| YES1   | >1,000 | 4.1 ± 0.2 | ~1,000 |

Results are average ± error of 2 independent experiments.
Epidermal Growth Factor (EGF) Receptor Inhibition in HT-1376 Bladder Carcinoma Cell line: HT-1376 cells (ATCC), were plated at 100,000 cells/well in a 96-well deep well plate, and incubated with inhibitor for 2 hours at 37°C. EGF (100 ng/mL) was added to induce EGFR phosphorylation signaling. After 5 minutes, cells were fixed in paraformaldehyde (1.6% final concentration) for 10 minutes at 37°C, followed by membrane permeabilization with 600 μL/well ice-cold 100% methanol for 30 minutes on ice. Cells were washed twice with PBS+BSA (0.5%). Cells were stained with rabbit anti p-EGFR (Y1069) (Cell Signaling) followed by a secondary anti-rabbit Ig-Alexa 647 (BD Biosciences). Flow cytometry was performed and median fluorescence values were obtained. The dynamic range between unstimulated and stimulated conditions for p-EGFR was greater than 10-fold. Wells without EGF served as a negative control.

| Cmpd | pEGFR (EC50)          |
|------|-----------------------|
| 1    | > 10,000 nM           |
| 2    | 47 nM                 |
| 3    | 68% inhibition at 10 μM |

Figure S1. Effect of BTK inhibitors on HT-1376 cell line. Dose response data of BTK inhibitor 1, 2 or 3 on EGFR phosphorylation signaling. The y-axis shows the percent of control where 100% represents the value in the EGF-stimulated/no inhibitor condition, whereas 0% (dotted line) represents the value of the unstimulated/no inhibitor condition. EC50 values could only be calculated for 2, as it was the only compound that showed complete inhibition over the concentration range tested.
Figure S2. Plasma time-concentration profile for acalabrutinib in healthy adult volunteers after oral administration of two doses of 2.5, 5, 25, 50 mg twelve hours apart on a single day, or a single dose of either 75 or 100 mg (Study ACE-HV-001).
Table S5: Summary of acalabrutinib PK parameters in healthy volunteers for oral administration of two doses of 2.5, 5, 25, 50 mg twelve hours apart on a single day, or a single dose of either 75 or 100 mg.

| Cohort | Treatment | Description | T_{max} (hr)* | C_{max} (ng/ml) | t_{1/2} (hr) | AUC_{0-12} (hr*ng/mL) | AUC_{0-24} (hr*ng/mL) | AUC_{0-inf} (hr*ng/mL) | CL/F (L/hr) | Vz/F (L) |
|--------|-----------|-------------|---------------|----------------|-------------|----------------------|----------------------|-------------------------|-------------|---------|
| 1      | 2x 2.5 mg | Mean ± SD (CV%) | 0.50 | 3.55 ± 1.89 | 2.14 ± 0.745 | 17.7 ± 5.37 | 27.8 ± 2.91 | 30.5 ± 2.52 | 165 ± 13.5 | 515 ± 198 |
| 2      | 2x 5 mg   | Mean ± SD (CV%) | 1.00 | 5.75 ± 2.72 | 1.83 ± 0.790 | 26.6 ± 10.1 | 45.1 ± 13.1 | 48.1 ± 11.9 | 219 ± 58  | 612 ± 414 |
| 3      | 2x 25 mg  | Mean ± SD (CV%) | 0.50 | 125 ± 44.5  | 1.06 ± 0.586 | 185 ± 62.1  | 305 ± 61   | 307 ± 60.2  | 169 ± 42.1 | 287 ± 259 |
| 4      | 2x 50 mg  | Mean ± SD (CV%) | 0.50 | 223 ± 98.2  | 0.884 ± 0.091 | 311 ± 77.6  | 501 ± 121  | 503 ± 121  | 211 ± 64  | 270 ± 91.1 |
| 5      | 1x 75 mg  | Mean ± SD (CV%) | 0.5   | 404 ± 229   | 6.94 ± 14.4  | 441 ± 121** | 437 ± 133 | 455 ± 104 | 172 ± 38.5 | 2120 ± 4590 |
| 6      | 1x 100 mg | Mean ± SD (CV%) | 0.5   | 580 ± 150   | 0.965 ± 0.171 | 632 ± 187   | 633 ± 188  | 633 ± 188  | 170 ± 49.9 | 233 ± 59.8 |

Abbreviations: AUC_{0-12h} = area under the plasma concentration time curve from time 0 to the 12 hour time point; AUC_{0-24h} = area under the plasma concentration time curve from time 0 to the 24 hour time point; AUC_{0-inf} = area under the plasma concentration time curve from time 0 to infinity; AUC_{0-t} = area under the plasma concentration time curve from time 0 to time t, where t is the last measurable concentration; CL/F = oral clearance; C_{max} = maximum concentration; N = sample size; SD = standard deviation; t_{1/2} = terminal elimination half-life; T_{max} = time to maximum concentration; Vz/F = volume of distribution. * Presented as median (minimum, maximum). ** AUC_{0-t} (hr*ng/mL).
Preparation of compounds

Acalabrutinib (ACP-196, 1), and analogues 7 – 9 and 11 – 16 were essentially prepared according the methods described in WO2013/010868A1. Ibrutinib (2) was purchased from Chembest (Shanghai, China). Spebrutinib (3) was prepared according the methods described in WO2009/158571.

Preparation of 4: 4-[8-amino-3-[(2R)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide. Synthesis is identical to 1, except Z-Pro-OH was replaced with Z-D-Pro-OH. LC-MS Rt: 3.621 min; m/z 466.1 (M+H)+. HPLC Rt: 4.367 min; purity: 99.7%. 1H NMR (400 MHz, DMSO-d6, 300K): δ 10.86 (s, 1H), 8.41 (m, 1H), 8.23 (d, 1H, J = 8.3 Hz), 8.16 (m, 2H), 7.86 (m, 1.3H), 7.80 (d, 0.6H, J = 5.1 Hz), 7.73 (t, 2H, J = 7.2 Hz), 7.18 (m, 1.4H), 7.13 (d, 0.6H, J = 5.0 Hz), 6.22 (s, 0.8H), 6.15 (s, 1.2H), 5.72 (m, 0.6H), 5.48 (m, 0.6H), 3.83 (t, 1.2H, J = 6.6 Hz), 3.61 (m, 0.8H), 2.48 – 2.04 (m, 3.2H), 2.01 (s, 2H), 1.95 (m, 0.8H), 1.62 (s, 1H).

Preparation of 5: 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(3-pyridyl)benzamide. Synthesis is identical to 1, using N-(3-pyridyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. LC-MS Rt: 2.977 min; m/z 466.3 (M+H)+. HPLC Rt: 3.414 min; purity: 98.9%. 1H NMR (400 MHz, DMSO-d6, 300K): δ 10.55 (s, 1H), 8.97 (d, 1H, J = 2.1 Hz), 8.33 (dd, 1H, J1 = 1.4 Hz, J2 = 4.8 Hz), 8.23 (m, 1H), 8.12 (dd, 2H, J1 = 2.1 Hz, J2 = 8.6 Hz), 7.87 - 7.76 (m, 3H), 7.42 (dd, 1H, J1 = 4.8 Hz, J2 = 8.6 Hz), 7.15 (m, 1H), 6.20 (s, 0.8H), 6.14 (s, 1.2H), 5.73 (m, 0.4H), 5.47 (m, 0.6H), 3.83 (m, 1.2H), 3.60 (m, 0.8H), 2.42 – 2.04 (m, 3 H), 2.02 (s, 3H), 1.63 (s, 1H).

Preparation of 6: 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(4-pyridyl)benzamide. Synthesis is identical to 1, using N-(4-pyridyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide and isolated as the 2,2,2-trifluoroacetic acid (TFA) salt. LC-MS Rt: 2.773 min; m/z 466.4 (M+H)+. HPLC Rt: 0.891 min; purity: 98.5%. 1H NMR (400 MHz, DMSO-d6, 300K): δ 11.53 (s, 1H), 8.77 (d, 2H, J = 7.1 Hz), 8.30 (d, 2H, J = 7.3 Hz), 8.21 (d, 2H, J = 8.6 Hz), 8.12 (d, 0.3H, J = 6.0 Hz), 8.05 (d, 0.7H, J = 6.0 Hz), 7.88 (m, 2H), 7.26 (d, 0.3H, J = 5.7 Hz), 7.21 (d, 0.7H, J = 5.8 Hz), 5.83 (m, 0.3H), 5.54 (m, 0.7H), 3.83 (m, 1.4H), 3.60 (m, 0.6H), 2.55 – 2.10 (m, 5H), 2.015 (s, 2.2H), 1.744 (s, 0.8H).
Preparation of BTK target occupancy probe N-[[3-[[2-[[3-[[5-[[3aS,4S,6aR]-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propyl]-N’-[[2-[[4-[[E]-4-[[2S]-2-amino-1-[4-(2-pyridylcarbamoyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-piperidyl]-4-oxo-but-2-enyl]piperazin-1-yl]ethyl]pentanediamide (ACP-4016, 10).

Benzyl (2S)-2-[[3-chloropyrazin-2-yl]methylcarbamoyl]piperidine-1-carboxylate. 2-Chloro-3-aminomethylpyrazine.HCl (2 g; 11.1 mmol), (S)-(-)-1-(carbobenzyloxy)-2-piperidine carboxylic acid (3.2 g; 12.2 mmol) and N,N-diisopropylethylamine (7.7 mL; 44.4 mmol) were dissolved in dichloromethane (100 mL). HATU (6.3 g; 16.7 mmol) was added and the resulting mixture was stirred overnight at room temperature. The mixture was washed with aqueous sodium bicarbonate solution and water. The organic layer was then dried over sodium sulfate, filtered and evaporated to dryness. The crude material was chromatographed over SiO₂ using a gradient of 20-80% ethyl acetate in heptane to give 4.4 g; 11.3 mmol of benzyl (2S)-2-[[3-chloropyrazin-2-yl]methylcarbamoyl]piperidine-1-carboxylate as a colorless oil (73%). LC-MS Rt: 5.85 min; m/z 389.2 (M+H)+. HPLC Rt: 8.30 min; purity 75%. ¹H NMR (400 MHz, CDCl₃, 300K): δ 8.35 (1H, d), 8.29 (1H, d), 7.35 (5H, br s), 5.20 (2H, s), 4.95 (1H, s), 4.76 (1H, d), 4.60 (1H, dd), 4.18 (1H, br s), 3.03 (1H, br s), 2.36 (1H, bd), 1.88 – 1.47 (6H, m).

Benzyl (2S)-2-[[8-chloroimidazo[1,5-a]pyrazin-3-yl]piperidine-1-carboxylate. Benzyl (2S)-2-[[3-chloropyrazin-2-yl]methylcarbamoyl]piperidine-1-carboxylate (4.4 g; 11.3 mmol) was dissolved in acetonitrile (100 mL). Phosphorus oxychloride (3.2 mL; 34.0 mmol) was added dropwise, followed by DMF (88 µL; 1.1 mmol). The mixture was stirred at 20°C overnight, and then diluted with DCM (250 mL). Aq. sodium bicarbonate solution (100 mL) was added slowly and the mixture was stirred until gas evolution ceased. The organic layer was dried on sodium sulfate, filtered and evaporated to dryness. Flash SiO₂ chromatography using a gradient of 0-50% of EtOAc in heptane yielded 2.3 g; 6.2 mmol of benzyl (2S)-2-[[8-chloroimidazo[1,5-a]pyrazin-3-yl]piperidine-1-carboxylate as a light yellow oil (55%). LC-
Benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate. Benzyl (2S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate (2.3 g; 6.2 mmol) was dissolved in DMF (25 mL). N-Bromosuccinimide (1.2 g; 6.8 mmol) was added under stirring. The mixture was stirred at room temperature for 4 hours. DCM (200 mL) and aqueous sodium bicarbonate solution (100 mL) were added to the mixture, and the layers were separated. The organic layer was dried over sodium sulfate, filtered and evaporated to dryness. Flash SiO₂ chromatography using a gradient of 0-100% of EtOAc in heptane yielded 2.7 g; 6.0 mmol of benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate as a beige solid (96%). LC-MS Rt: 7.69 min; m/z 450.1 (M+H)⁺. HPLC Rt: 11.18 min; purity 88.8%. ¹H NMR (400 MHz, CDCl₃, 300K): δ 7.94 (1H, br s), 7.36 (5H, m), 7.17 (1H, s), 5.76 (1H, s), 5.19 (2H, m), 4.00 (1H, d, J = 13.6), 2.73 (1H, dt, J₁ = 13.2, J₂ = 2.8), 2.34 (2H, m), 1.96 (1H, m), 1.80 (1H, d, J = 13.2), 1.72 (1H, d, J = 13.2), 1.54 (1H, m).

Benzyl (2S)-2-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate. Benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate (2.7 g; 6.0 mmol) was suspended in isopropanol (20 mL) and aqueous ammonia (20 mL), and transferred into two microwave vials (20 mL max. capacity). The vials were capped and heated to 125°C for a total of 2.5 hours each. The mixture was evaporated to dryness. The crude product was purified by flash SiO₂ chromatography using a gradient of 0-5% of MeOH in DCM to give 2.2 g; 5.0 mmol of benzyl (2S)-2-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate as a yellow solid (83%). LC-MS Rt: 4.70 min; m/z 431.1 (M+H)⁺. HPLC Rt: 6.27 min; purity 96.0%. ¹H NMR (400 MHz, DMSO-d₆, 300K): δ 7.47 (1H, br d), 7.32 (5H, m), 6.95 (1H, s), 6.71 (2H, s), 5.68 (1H, m), 5.13 (2H, m), 3.90 (1H, m), 3.04 (1H, br t), 1.94
(3H, m), 1.65 (2H, m), 1.44 (1H, m).

Benzyl (2S)-2-[8-amino-1-[4-(2-pyridylcarbamoyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]piperidine-1-carboxylate.

Benzyl (2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate (1 g; 2.3 mmol) and 4-(pyridine-2-yl)aminocarbonylphenylboronic acid (562 mg; 2.3 mmol) were dissolved in dioxane (16 mL). 2M potassium carbonate solution in water (4 mL) was added. The mixture was purged with N₂ for 5 minutes, after which 1,1′-bis(diphenylphosphino)ferrocene)dichloropalladium(II), complex with dichloromethane (95 mg; 0.12 mmol) was added. The resulting mixture was heated to 140°C for 25 minutes. The mixture was diluted with DCM (50 mL) and washed with water (25 mL). The organic layer was dried over sodium sulfate, filtered and evaporated to dryness to give a light brown oil. The crude product was purified by flash SiO₂ chromatography using a gradient of 0-5% of MeOH in DCM to give 1.2 g; 2.1 mmol of benzyl (2S)-2-[8-amino-1-[4-(2-pyridylcarbamoyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]piperidine-1-carboxylate as a yellow oil (91%). LC-MS Rt: 5.04 min; m/z 548.2 (M+H)+. HPLC Rt: 6.86 min; purity 97.0%. ¹H NMR (400 MHz, DMSO-d₆, 300K): δ 10.86 (1H, s), 8.41 (1H, m), 8.24 (1H, d, J = 8.3), 8.17 (2H, d, J = 8.5), 7.86 (1H, m), 7.76 (2H, d, J = 8.4), 7.54 (1H, br s), 7.31 (5H, br s), 7.19 (1H, m), 7.05 (1H, br s), 6.21 (2H, s), 5.79 (1H, d, J = 5.0), 5.15 (2H, m), 3.95 (1H, d, J = 13.6), 3.18 (1H, br s), 2.14 (2H, br s), 1.90 (1H, m), 1.70 (2H, m), 1.49 (1H, m).
4-[8-Amino-3-[(2S)-2-piperidyl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide. Benzyl (2S)-2-[8-amino-1-[4-(2-pyridyl)carbamoyl]phenyl]imidazo[1,5-a]pyrazin-3-yl]piperidine-1-carboxylate (1.2 g; 2.1 mmol) was dissolved in 33% HBr in acetic acid (20 mL) and held at room temperature overnight. The mixture was diluted with water (150 mL) and washed with dichloromethane (100 mL). The aqueous layer was made basic using 2N aqueous sodium hydroxide solution, and then extracted with dichloromethane (200 mL). The organic layer was dried over sodium sulfate, filtered and evaporated to dryness to give 715 mg; 1.7 mmol of 4-[8-amino-3-[(2S)-2-piperidyl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide as a yellow solid (79%). LC-MS Rt: 1.70 min; m/z 414.2 (M+H)+. HPLC Rt: 0.47 min; purity 99.0%. 1H NMR (400 MHz, DMSO-d6, 300K): δ 10.84 (1H, s), 8.42 (1H, m), 8.23 (1H, d, J = 8.3), 8.16 (2H, d, J = 8.5), 7.93 (1H, d, J = 4.9), 7.85 (1H, m), 7.75 (2H, d, J = 8.5), 7.18 (1H, m), 7.07 (1H, d, J = 4.9), 6.12 (2H, br s), 4.14 (1H, m), 3.00 (1H, d, J = 11.7), 2.69 (2H, t, J = 11.0), 1.88 (3H, m), 1.54 (3H, m).

Ethyl (E)-4-[4-[(2-tert-butoxycarbonylamino)ethyl]piperazin-1-yl]but-2-enoate. A mixture of tert-butyl N-(2-piperazin-1-ylethyl)carbamate (1 g; 4.4 mmol), potassium carbonate (1.2 g, 8.7 mmol) and ethyl (E)-4-bromobut-2-enoate (674 µL, 4.9 mmol) in ethanol (15 mL) was stirred at room temperature for 3 hours. The mixture was diluted with ethyl acetate (20 mL) and washed with water (20 mL). The organic layer was dried over sodium sulfate, filtered and evaporated to dryness to give a dark brown oil. The crude product was purified by silica column chromatography (0 to 10% methanol in dichloromethane) to give 895 mg; 2.6 mmol of ethyl (E)-4-[4-[(2-tert-butoxycarbonylamino)ethyl]piperazin-1-yl]but-2-enoate as a yellow oil (60%). LC-MS Rt: 3.67 min; m/z 342.3 (M+H)+. 1H NMR (400 MHz, DMSO-d6, 300K): δ 6.78 (1H, dt, J1 = 15.7, J2 = 5.9), 6.62 (1H, t, J = 5.3), 5.99 (1H, dt, J1 = 15.7, J2 = 1.6), 4.11 (2H, q, J = 7.1), 3.09 (2H, dd, J1 = 6.0, J = 1.6), 3.01 (2H, m), 2.31 (10H, m), 1.37 (9H, s), 1.21 (3H, t, J = 7.1).

(E)-4-[4-[(2-tert-butoxycarbonylamino)ethyl]piperazin-1-yl]but-2-enoic acid. A mixture of potassium hydroxide (2
mL, 4 mmol) and ethyl (E)-4-[4-2-(tert-butoxycarbonylamino)ethyl]piperazin-1-yl]but-2-enoate (673 µL, 2.6 mmol) in tetrahydrofuran (20 mL) was stirred at room temperature for 3 hours. Mainly starting material, some desired product was observed. Potassium hydroxide (2 mL, 4 mmol) was added and the reaction mixture was stirred overnight at room temperature. Still some starting material left. 6N HCl (1.3 mL) was added and the reaction mixture was concentrated under reduced pressure. Then, 10 mL of methanol was added. The white precipitate was filtered off and the filtrate was concentrated under reduced pressure to give 910 mg; 2.4 mmol of (E)-4-[4-2-(tert-butoxycarbonylamino)ethyl]piperazin-1-yl]but-2-enoic acid as a light brown solid (93%). LC-MS Rt: 2.60 min; m/z 314.3 (M+H)^+. \(^1\mathrm{H}\) NMR (400 MHz, DMSO-d6, 300K): \(\delta\) 6.73 (1H, dt, \(J_1 = 15.7\), \(J_2 = 6.1\)), 6.65 (1H, t, \(J = 5.3\)), 5.3 (1H, d, \(J = 15.7\)), 3.08 (2H, dd, \(J = 6.1\)), 3.02 (2H, m), 2.35 (10H, m), 1.37 (9H, s).

tert-Butyl \(N\)-[2-[4-[(E)-4-[(2S)-2-[8-amino-1-[4-(2-pyridylicarbamoyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-piperidyl]-4-oxo-but-2-enyl]piperazin-1-yl]ethy]lcarbamate. A solution of 4-[8-amino-3-[[2S]-2-piperidyl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide (250 mg; 0.60 mmol), (E)-4-[4-2-(tert-butoxycarbonylamino)ethyl]piperazin-1-yl]but-2-enoic acid (271 mg; 0.73 mmol), HATU (345 mg; 0.91 mmol) and N,N-diisopropylethylamine (400 µL; 2.41 mmol) in dichloromethane (10 mL) was stirred at room temperature for 2 hours. Water (10 mL) was added to the mixture and stirred for 10 minutes. The organic layer was dried over sodium sulfate, filtered and evaporated to dryness to give a yellow oil. The crude product was purified by silica column chromatography (0 to 10% methanol in dichloromethane) to give 262 mg; 0.37 mmol of tert-butyl \(N\)-[2-[4-[(E)-4-[(2S)-2-[8-amino-1-[4-(2-pyridylicarbamoyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-piperidyl]-4-oxo-but-2-enyl]piperazin-1-yl]ethyl]carbamate as a brown oil (61%). LC-MS Rt: 3.92 min; m/z 709.4 (M+H)^+; 707.3 (M+H)^+. \(^1\mathrm{H}\) NMR (400 MHz, DMSO-d6, 300K): \(\delta\) 10.85 (1H, s), 8.41 (1H, m), 8.23 (1H, m), 8.16 (2H, m), 7.86 (1H, m), 7.77 (2H, d, \(J = 8.2\)), 7.55 (1H, d, \(J = 4.9\)), 7.19 (1H, m), 7.12 (1H, d, \(J = 4.9\)), 6.70-6.59 (2H, m), 6.21 (2H, s), 3.90 (1H, br
s), 3.49 (1H, br s), 3.20-2.94 (4H, m), 2.47-1.40 (18H, m), 1.37 (9H, s).

4-\{8-Amino-3-\{(2S)-1-\{(E)-4-\{4-(2-aminoethyl)piperazin-1-yl\}but-2-enoyl\}-2-piperidyl\}imidazo[1,5-a]pyrazin-1-yl\}-N-(2-pyrdyl)benzamide. tert-Butyl N-\{2-\{(E)-4-\{(2S)-2-\{8-amino-1-\{4-(2-pyridylcarbamoyl)phenyl\}imidazo[1,5-a]pyrazin-3-yl\}-1-piperidyl\}-4-oxo-but-2-enyl\}piperazin-1-yl\}ethyl\}carbamate (260 mg; 0.37 mmol) was dissolved in dichloromethane (20 mL) and trifluoroacetic acid (5 mL) and stirred at room temperature for 2 hours. Aqueous 2N sodium hydroxide was added to the mixture until neutral. The organic layer was dried over sodium sulfate, filtered and evaporated to dryness to give 175 mg; 0.29 mmol of 4-\{8-amino-3-\{(2S)-1-\{(E)-4-\{4-(2-aminoethyl)piperazin-1-yl\}but-2-enoyl\}-2-piperidyl\}imidazo[1,5-a]pyrazin-1-yl\}-N-(2-pyrdyl)benzamide as a yellow solid (78% crude). LC-MS Rt: 2.76 min; m/z 609.4 (M+H)⁺. HPLC Rt: 0.98 min; purity 87.5%. ¹H NMR (400 MHz, DMSO-d₆, 300K): δ 10.85 (1H, br s), 8.41 (1H, m), 8.23 (1H, dt, J = 8.3), 8.17 (2H, d, J = 8.5), 7.86 (1H, m), 7.78 (2H, d, J = 7.2), 7.56 (1H, d, J = 4.2), 7.18 (1H, t), 7.12 (1H, d, J = 4.8), 6.67 (2H, br s), 6.20 (2H, br s), 3.91 (1H, m), 3.23-3.09 (4H, m), 2.61 (1H, t, J = 7.0), 2.37 (12H, m), 1.87-1.64 (4H, m), 1.47 (1H, m).

ACP-4016. N-biotinyl-NH(PEG)2-COOH (242 mg; 0.351 mmol) was dissolved in DMF (8 mL) under a nitrogen
atmosphere. N-hydroxysuccinimide (48.4 mg; 0.421 mmol) and N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (80.6 mg; 0.421 mmol) were added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was added dropwise to a solution of 4-[(8-amino-3-[(2S)-1-[(E)-4-(2-aminoethyl)piperazin-1-yl]but-2-enoxy]-2-piperidyl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide (175.1 mg; 0.288 mmol) and DIPEA (75.4 µL) in DMF (4 mL) at -10°C. The reaction mixture was allowed to warm to room temperature overnight, concentrated to half the volume under reduced pressure and then purified by preparative HPLC (column: Luna C-18, eluent 0-40% ACN in water + 0.5% TFA). The pure fractions were collected and converted to the free base using an SCX column (eluent: MeOH/DiPEA 9/1). The resulting solution was concentrated under reduced pressure, and then lyophilized from ACN/water 1/1 to give 138.8 mg; 0.120 mmol of N-[3-[2-[2-[3-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydropyrido[3,4-d]imidazol-4-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propyl]-N′-[2-[4-[(2S)-4-[(8-amino-1-[(4-pyridyldiamide)],imidazo[1,5-a]pyrazin-3-yl]-1-piperidyl]-4-oxo-but-2-enyl)piperazin-1-yl]ethyl]pentanediamide (ACP-4016, 10) (34%). LC-MS Rt: 3.58 min; m/z 1151.5 (M+H)+; m/z 1149.5 (M-H). HPLC Rt: 4.75 min; purity 99.4%. 1H NMR (400 MHz, CDCl 3, 300K): δ 8.80 (1H, s), 8.46 (1H, d, J = 8.5), 8.36 (1H, d, J = 4.7), 8.11 (2H, d, J = 8.0), 7.89 (2H, d, J = 8.1), 7.83 (1H, t), 7.66 (1H, s), 7.14 (1H, t), 7.10 (1H, d, J = 4.9), 7.00-6.88 (2H, m), 6.80 (1H, d, J = 15.2), 6.38 (1H, br s), 6.02 (1H, s), 5.40-5.20 (3H, m), 4.54 (1H, t), 4.36 (1H, t), 3.83 (1H, d, J = 12.3), 3.64-3.52 (13H, m) 3.38 (6H, m), 3. 18 (4H, m), 2.96 (1H, m), 2.76 (2H, m), 2.64-2.41 (11H, m), 2.24 (7H, m), 1.94 (3H, m), 1.93-1.54 (8H, m), 1.44 (3H, m).

**Preparation of 12:** 4-[(8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-thiazol-4-yl-benzamide. This compound is synthesized in an analogous manner as 1 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-thiazol-4-yl-benzamide, resulting in 15 mg of the title compound as a light yellow solid. LC-MS Rt: 3.96 min; m/z 472.5 (M+H)+. HPLC Rt: 8.43; purity 95.3%. 1H NMR (400 MHz, DMSO-d6, 300 K): δ 11.49 (1H, s), 9.05 (1H, d, J = 2.24), 8.16 (2H, dd J1 = 2.60, J2 = 8.38), 7.89-7.84 (1H, m), 7.81 (1H, d, J = 7.28), 7.74-7.71 (2H, m), 7.13 (1H, dd, J1 = 4.92, J2 = 15.76), 6.14 (2H, bs), 5.72-5.46 (1H, m), 3.83-3.80 (1H, t), 3.60-3.58 (1H, m), 2.49-2.36 (1H, m), 2.28-2.10 (2H, m), 2.05-1.92 (3H, m), 1.62 (1H, s).

**Preparation of 13:** 4-[(8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-thiazol-5-yl-benzamide. This compound is synthesized in an analogous manner as 1 using 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-N-thiazol-5-yl-benzamide, resulting in 5 mg of the title compound as a light yellow solid. LC-MS Rt: 3.82 min; m/z 472.17 (M+H)^+. HPLC Rt: 10.24 min; purity 97.7%. ^1H NMR (400 MHz, DMSO-d6, 300 K): δ 11.88 (1H, s), 8.64 (1H, s), 8.13 (2H, d, J = 8.3), 7.81 (4H, m), 7.14 (1H, dd, J1 = 16.1, J2 = 5.0), 6.19 (0.8H, br s), 6.13 (1.2H, br s), 5.72 (0.4H, m), 5.48 (0.6H, m), 3.82 (1H, m), 3.60 (1H, m), 2.50-2.19 (2H, m), 2.14-1.94 (4.8H, m), 1.62 (1.2H, s).

Preparation of 14: 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-methyl-N-(2-pyridyl)benzamide.

N-methyl-N-(2-pyridyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (650 mg, 2.62 mmol), EDCI (553 mg, 2.88 mmol) and DMAP (38.4 mg, 0.31 mmol) were dissolved in DCM (10 mL). N-methylpyridin-2-amine (297 uL, 2.88 mmol) was added. The reaction mixture was stirred overnight at 21 ºC. The organic layer was washed twice with water (10 mL), dried using a PE-filter and concentrated in vacuo. The crude product was purified using flash chromatography (0-10% methanol in DCM) to give 367 mg of N-methyl-N-(2-pyridyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide as a white solid. LC-MS Rt: 6.12 min; m/z 339.2 (M+H)^+.

4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-methyl-N-(2-pyridyl)benzamide. This compound is synthesized in an analogous manner as 1 using N-methyl-N-(2-pyridyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, resulting in 43 mg of the title compound as a light yellow solid. LC-MS Rt: 3.65 min; m/z 480.2 (M+H)^+. HPLC Rt: 4.49 min; purity 100%. ^1H NMR (400 MHz, DMSO-D6, 300K): δ 8.41 (1H, m), 7.75 - 7.85 (1H, dd, , J1 = 28.7 Hz, J2 = 5.2 Hz), 7.71 (1H, t, J = 7.3 Hz), 7.50 (2H, t, J1 = 8.5 Hz, J2 = 7.4 Hz), 7.39 (2H, d, J = 7.9 Hz), 7.16 - 7.23 (2H, m), 7.07 - 7.14 (1H, dd, , J1 = 15.9 Hz, J2 = 5.0 Hz), 6.05 (1H, br s), 5.98 (1H, br s), 5.42 - 5.72 (1H, m), 3.81 (1H, m), 3.58 (1H, m), 3.49 (3H, s), 2.15 - 2.46 (2H, m), 2.09 (1H, m), 2.02 (2H, s), 1.98 (1H, m), 1.60 (1H, s).

Preparation of 15: 4-[8-Amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]benzamide.

Benzyl (2S)-2-[8-amino-1-(4-cyanophenyl)imidazo[1,5-a]pyrazin-3-yl]pyrrolidine-1-carboxylate. A solution of benzyl (2S)-2-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate (500 mg, 1.2 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (302 mg, 1.32 mmol), 2M aqueous potassium carbonate
solution (1.8 mL, 3.6 mmol) in 1,4-dioxane (10 mL) was degassed for 5 minutes. Then PdCl2(dppf) (49 mg, 0.06 mmol) was added and the reaction mixture was again degassed for 5 minutes. The reaction mixture was heated at 100 °C for 16 hours in a sealed tube. After completion, the reaction mixture was diluted with water (25 ml) and extracted with ethyl acetate (25 ml). The organic layer was dried over sodium sulfate and concentrated to get the crude mass which was purified by column chromatography (silica: 100-200; elution: 3-4% methanol in dichloromethane) to get 500 mg (1.14 mmol) benzyl (2S)-2-[8-amino-1-(4-cyanophenyl)imidazo[1,5-a]pyrazin-3-yl]pyrrolidine-1-carboxylate as pale yellow solid (95%). LC-MS Rt: 2.04 min; m/z 439.20 (M+H)^+. 1H NMR (400 MHz, DMSO-d6, 300 K): δ 7.92 (2H, d, J= 8.4 Hz), 7.80-7.74 (3H, m), 7.66 (1H, d, J= 4.4 Hz), 7.31 (2H, s), 7.13 (1H, s), 7.07-7.03 (1H, m), 6.73 (1H, d, J= 7.2 Hz), 6.19 (2H, s), 5.42-5.40 (1H, m), 5.01 (2H, s), 3.62-3.54 (2H, m), 2.32-2.19 (2H, m), 2.15-1.95 (2H, m).

4-[8-Amino-3-[(2S)-pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]benzamide. A solution of benzyl (2S)-2-[8-amino-1-(4-cyanophenyl)imidazo[1,5-a]pyrazin-3-yl]pyrrolidine-1-carboxylate (500 mg, 1.14 mmol) in 33% HBr in acetic acid (5 mL) was stirred at room temperature for 16 hours. After completion, the reaction mixture was poured in water (50 ml) and extracted with ethyl acetate (50 ml). The aqueous layer was basified with solid sodium hydroxide and again extracted with ethyl acetate (50 ml). This organic layer was dried over anhydrous sodium sulfate and concentrated to get 250 mg (0.76 mmol) 4-[8-amino-3-[(2S)-pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]benzamide as yellow solid (68%). LC-MS Rt: 0.87 min; m/z 323.32 (M+H)^+. 1H NMR (400 MHz, DMSO-d6, 300 K): δ 8.03 (1H, s), 7.98 (2H, d, J= 8.0 Hz), 7.75 (1H, d, J= 4.8 Hz), 7.67 (2H, d, J= 4.8 Hz), 7.39 (1H, s), 7.05 (1H, d, J= 4.8 Hz), 6.04 (2H, s), 4.54-4.51 (1H, m), 2.90-2.86 (2H, m), 2.05 (1H, bs), 1.86-1.75 (2H, m), 1.38-1.29 (2H, m).

4-[8-Amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]benzamide. To a solution of 4-[8-amino-3-[(2S)-pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]benzamide (150 mg, 0.46 mmol) in dichloromethane (5 mL) was added but-2-ynoic acid (39 mg, 0.46 mmol), DIPEA (0.24 mL, 1.39 mmol) and T3P (0.41mL, 0.69 mmol) at 0 °C. The reaction mixture was stirred at same temperature for 30 minutes. After completion, the reaction mixture was diluted with water (10 ml) and extracted with dichloromethane (25 ml). The organic layer was dried over sodium sulfate and concentrated to get the crude material which was purified by column chromatography (silica: 100-200; elution: 8-10% methanol in dichloromethane) to get 40 mg; 0.10 mmol 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]benzamide as yellow solid (22%). LC-MS Rt: 3.18 min; m/z 389.0 (M+H)^+. HPLC Rt: 8.93 min; purity 99.3%. 1H NMR (400 MHz, DMSO-d6, 300 K): δ 8.04 (1H, s), 7.99 (2H, d, J = 8.3), 7.84 (0.4H, d, J = 5.0), 7.78 (0.6H, d, J = 5.0), 7.67 (2H, t, J = 6.8), 7.41 (1H, s), 7.13 (0.4H, d, J = 4.9), 7.10 (0.6H, d, J = 4.9),
6.15 (0.8H, br s), 6.11 (1.2H, br s), 5.70 (0.4H, m), 5.46 (0.6H, m), 3.81 (1H, m), 3.60 (1H, m), 2.40-2.15 (2H, m),
2.15-1.90 (4.8H, m), 1.62 (1.2H, s).

**Preparation of 16:** 3-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-
pyridyl)benzamide. This compound is synthesized in an analogous manner as 14 using N-(2-pyridyl)-3-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, resulting in 30 mg of the title compound as a yellow solid. LC-MS
Rt: 3.62 min; m/z 466.3 (M+H)+. HPLC Rt: 4.84 min; purity 99.8%. 1H NMR (400 MHz, DMSO-d6, 300 K): δ 10.90
(1H, d, J = 4.6), 8.41 (1H, m), 8.23 (2H, m), 8.08 (1H, d, J = 7.2), 7.89-7.79 (3H, m), 7.65 (1H, t, J = 7.8), 7.19 (1H,
ddd, J1 = 7.4, J2 = 4.9, J3 = 1.0), 7.14 (1H, dd, J1 = 15.9, J2 = 5.0), 6.16 (0.8H, br s), 6.09 (1.2H, br s), 5.74 (0.4H,
m), 5.49 (0.6H, m), 3.83 (1H, t, J = 6.5), 3.61 (1H, m), 2.47-2.20 (2H, m), 2.20-1.95 (4.8H, m), 1.65 (1.2H, s).

**HPLC Method for Glutathione Reactivity Assay:** A Gilson-system equipped with a Phenomenex Luna C18(2) (150
x 2.00 mm, 5µm) column and UV/Vis detector (210/240 nm). The used method was a 25-minute run, using a
continuous flow (1 mL/min). Eluens: A: acetonitrile, B: acetronitrile / MilliQ-water = 1/9 (v/v), C: 0.1% TFA in
MilliQ-water.

| Time (min) | A (%) | B (%) | C (%) |
|------------|-------|-------|-------|
| 0.00       | 0     | 97    | 3     |
| 11.90      | 97    | 0     | 3     |
| 14.40      | 97    | 0     | 3     |
| 15.40      | 0     | 97    | 3     |
| 25.00      | 0     | 97    | 3     |
Supporting References

1. Krippendorff BF, Neuhaus R, Lienau P, Reichel A, and Huisinga W (2009) Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values *J Biomol Screen* **14**: 913–923.

2. Olsson MH, Søndergaard CR, Rostkowski M, and Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. *J Chem Theory Comp* **7**, 525-537.

3. Molecular Operating Environment (MOE), 2015.10, 1015.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.